Wird geladen...
Both cladribine and alemtuzumab may effect MS via B-cell depletion
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...
Gespeichert in:
| Veröffentlicht in: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Lippincott Williams & Wilkins
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://ncbi.nlm.nih.gov/pubmed/28626781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000360 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|